Methylenetetrahydrofolate reductase C677T polymorphism, hypertension and risk of stroke: a prospective, nested case-control study

References

• Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 2002;325:1202–6.
   PubMed Web of Science ®Google Scholar
• Clarke R, Collins R, Lewington S, et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015–22.
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C →T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529–36.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002;112:556–565.
   PubMed Web of Science ®Google Scholar
• Lucock M, Yates Z. Folic acid – vitamin and panacea or genetic time bomb? Nat Rev Genet 2005;6(3):235–40.
   PubMed Web of Science ®Google Scholar
• Casas JP, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from Mendelian randomization. Lancet 2005;365(9455):224–32.
   PubMed Web of Science ®Google Scholar
• Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease – a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–13.
   PubMed Web of Science ®Google Scholar
• Zhang MJ, Li JC, Yin YW, et al. Association of MTHFR C677T polymorphism and risk of cerebrovascular disease in Chinese population: an updated meta-analysis. J Neurol 2014;261(5):925–35.
   PubMed Web of Science ®Google Scholar
• Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomized trials. Lancet 2011;378(9791):584–94.
   PubMed Web of Science ®Google Scholar
• Hultdin J, Van Guelpen B, Winkvist A, et al. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>Cgenotypes and haplotypes – evidence for an association with hemorrhagic stroke. Clin Chem Lab Med 2011;49(9):1555–62.
   PubMed Web of Science ®Google Scholar
• Zhang W, Sun K, Chen J, et al. High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clin Sci (Lond) 2009;118(3):187–94.
   PubMed Web of Science ®Google Scholar
• Saraswathy KN, Garg PR, Salam K, et al. MTHFR C677T polymorphism and its homocysteine-driven effect on blood pressure. Int J Stroke 2014;9(4):E20.
   PubMed Web of Science ®Google Scholar
• Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003;49(8):1292–6
   PubMed Web of Science ®Google Scholar
• Castro R, Rivera I, Ravasco P, et al. 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C–>T and 1298A–>C mutations are associated with DNA hypomethylation. J Med Genet 2004;41(6):454–8.
   PubMed Web of Science ®Google Scholar
• Friso S, Choi SW, Girelli D, et al. A common mutation inthe 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99(8):5606–11.
   PubMed Web of Science ®Google Scholar
• Aarabi M, San Gabriel MC, Chan D, et al. High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFRC677T polymorphism. Hum Mol Genet 2015;24(22):6301–13.
   PubMed Web of Science ®Google Scholar
• Wei LK, Sutherland H, Au A, et al. A potential epigenetic marker mediating serum folate and vitamin B12 levels contributes to the risk of ischemic stroke. Biomed Res Int 2015;2015:167976.
   PubMed Web of Science ®Google Scholar
• Macis D, Maisonneuve P, Johansson H, et al. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 2007;106(2):263–71.
   PubMed Web of Science ®Google Scholar
• Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361(9370):1693–9.
   PubMed Web of Science ®Google Scholar
• Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277(22):1775–81.
   PubMed Web of Science ®Google Scholar
• Pezzini A, Grassi M, Del Zotto E, et al. Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke 2005;36(3):533–9.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Bowman L, Clarke RJ, et al. Study of the effectiveness of additional reductions in cholesterol and homocysteine collaborative group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303(24):2486–94.
   PubMed Web of Science ®Google Scholar
• VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the Vitamins to prevent stroke (VITATOPS) trial: a randomized, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9(9):855–65.
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, et al. Heart outcomes prevention evaluation 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354(15):1567–77.
   PubMed Web of Science ®Google Scholar
• Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291(5):565–75.
   PubMed Web of Science ®Google Scholar
• Galan P, Kesse-Guyot E, Czernichow S, et al. SU.FOL.OM3 collaborative group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomized placebo controlled trial. BMJ 2010;341:c6273.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT trial investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578–88.
   PubMed Web of Science ®Google Scholar
• Jamison RL, Hartigan P, Kaufman JS, et al. Veterans affairs site investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298(10):1163–70.
   PubMed Web of Science ®Google Scholar
• Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299(17):2027–36.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008;300(7):795–804.
   PubMed Web of Science ®Google Scholar
• Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369(9576):1876–82.
   PubMed Web of Science ®Google Scholar
• Huo Y, Li J, Qin X, et al. CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015;313(13):1325–35.
   PubMed Web of Science ®Google Scholar